CYP7A1 and metabolic dysfunction-associated steatotic liver disease: Ginsenoside Re ameliorated NAFLD by modulating gut microbiota to upregulate hepatic FXR signaling, thereby inhibiting BA synthesis by upregulating CYP7A1 and reducing hepatic lipid accumulation, while concurrently repairing intestinal barrier and suppressing liver inflammation (Zheng et al., 2025).